Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Raised Cholesterol. Available online: https://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/ (accessed on 21 November 2021).
- Virani, S.S.; Alonso, A.; Aparicio, H.J.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics–2021 Update. A Report from the American Heart Association. Circulation 2021, 143, e254–e743. [Google Scholar] [CrossRef]
- Kontsevaya, A.; Shalnova, S.; Deev, A.; Breda, J.; Jewell, J.; Rakovac, I.; Conrady, A.; Rotar, O.; Zhernakova, Y.; Chazova, I.; et al. Overweight and obesity in the Russian Population: Prevalence in adults and association with socioeconomic parameters and cardiovascular risk factors. Obes. Facts 2019, 12, 103–114. [Google Scholar] [CrossRef] [PubMed]
- Shalnova, S.A.; Drapkina, O.M. Contribution of the ESSE-RF study to preventive healthcare in Russia. Cardiovasc. Ther. Prev. 2020, 3, 2602. (In Russian) [Google Scholar] [CrossRef]
- Boytsov, S.A.; Drapkina, O.M.; Shlyakhto, E.V.; Konradi, A.O.; Balanova, Y.A.; Zhernakova, Y.V.; Metelskaya, V.A.; Oshchepkova, E.V.; Rotar, O.P.; Shalnova, S.A. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovasc. Ther. Prev. 2021, 5, 3007. (In Russian) [Google Scholar] [CrossRef]
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017, 389, 37–55. [Google Scholar] [CrossRef] [Green Version]
- Shalnova, S.A.; Vilkov, V.G.; Metelskaya, V.A.; Balanova, Y.A.; Kapustina, A.V. Thirty-Year Changes in Average Blood Lipids Levels in Populations of the Russian Federation and the USA. Ration. Pharmacother. Cardiol. 2018, 1, 4–11. (In Russian) [Google Scholar] [CrossRef]
- Maksimov, S.A.; Shalnova, S.A.; Balanova, Y.A.; Kutsenko, V.A.; Evstifeeva, S.E.; Imaeva, A.E.; Drapkina, O.M. What regional living conditions affect individual smoking of adults in Russia. Int. J. Public Health 2021, 66, 599570. [Google Scholar] [CrossRef]
- Farzadfar, F.; Finucane, M.M.; Danaei, G.; Pelizzari, P.M.; Cowan, M.J.; Paciorek, C.J.; Singh, G.M.; Lin, J.K.; Stevens, G.A.; Riley, L.M.; et al. National, regional, and global trends in serum total cholesterol since 1980: Systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants. Lancet 2011, 377, 578–586. [Google Scholar] [CrossRef]
- NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature 2020, 582, 73–77. [Google Scholar] [CrossRef] [PubMed]
- NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: A pooled analysis of 458 population-based studies in Asian and Western countries. Int. J. Epidemiol. 2020, 49, 173–192. [Google Scholar] [CrossRef] [PubMed]
- Metelskaya, V.A.; Shalnova, S.A.; Deev, A.D.; Perova, N.V.; Gomyranova, N.V.; Litinskaya, O.A.; Evstifeeva, S.E.; Artamonova, G.V.; Gatagonova, T.M.; Grinshtein, Y.I.; et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (Results of the ESSE-RF Study). Prev. Med. 2016, 1, 15–23. (In Russian) [Google Scholar] [CrossRef]
- Ezhov, M.V.; Shalnova, S.A.; Yarovaya, E.B.; Kutsenko, V.A.; Evstifeeva, S.E.; Metelskaya, V.A.; Drapkina, O.M.; Boytsov, S.A. Lipoprotein(a) in an adult sample from the Russian population: Distribution and association with atherosclerotic cardiovascular diseases. Arch. Med. Sci. 2021, 1–8. [Google Scholar] [CrossRef]
- Unniachan, S.; Bash, L.D.; Khovidhunkit, W.; Sri, R.Z.; Vicaldo, E.; Recto, C., 2nd; Ambegaonkar, B.M. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: A pooled analysis of observational studies from five Asian countries. Int. J. Clin. Pract. 2014, 8, 1010–1019. [Google Scholar] [CrossRef]
- Gupta, R.; Rao, R.S.; Misra, A.; Sharma, S.K. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017, 69, 382–392. [Google Scholar] [CrossRef]
- Mahmoud, I.; Sulaiman, N. Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: A population-based study. BMJ Open 2019, 9, e031969. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Z.V.; Llanes, E.J.; Sukmawan, R.; Thongtang, N.; Tri, H.H.Q.; Barter, P.; on behalf of the Cardiovascular RISk Prevention (CRISP) in Asia Network. Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. Lipids Health Dis. 2021, 20, 33. [Google Scholar] [CrossRef] [PubMed]
- Meshkov, A.N.; Ershova, A.I.; Kiseleva, A.V.; Shalnova, S.A.; Drapkina, O.M.; Boytsov, S.A.; on Behalf of The FH-ESSE-RF Investigators. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. J. Pers. Med. 2021, 11, 464. [Google Scholar] [CrossRef] [PubMed]
- Borrayo-Sanchez, G. Epidemiology and burden of morbidity and mortality in dyslipidemias and atherosclerosis. Cardiovasc. Metab Sci. 2021, 32, s143–s146. [Google Scholar] [CrossRef]
- Toth, P.P.; Potter, D.; Ming, E.E. Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. J. Clin. Lipidol. 2012, 6, 325–330. [Google Scholar] [CrossRef]
- Carrillo-Larco, R.M.; Benites-Moya, C.J.; Anza-Ramirez, C.; Albitres-Flores, L.; Sánchez-Velazco, D.; Pacheco-Barrios, N.; Bernabe-Ortiz, A. A systematic review of population-based studies on lipid profiles in Latin America and the Caribbean. eLife 2020, 9, e57980. [Google Scholar] [CrossRef]
- Xing, L.; Jing, L.; Tian, Y.; Yan, H.; Zhang, B.; Sun, Q.; Dai, D.; Shi, L.; Liu, D.; Yang, Z.; et al. Epidemiology of dyslipidemia and associated cardiovascular risk factors in northeast China: A cross-sectional study. Nutr. Metab. Cardiovasc. Dis. 2020, 12, 2262–2270. [Google Scholar] [CrossRef] [PubMed]
- Espírito Santo, L.R.; Faria, T.O.; Silva, C.S.O.; Xavier, L.A.; Reis, V.C.; Mota, G.A.; Silveira, M.F.; Mill, J.G.; Baldo, M.P. Socioeconomic status and education level are associated with dyslipidemia in adults not taking lipid-lowering medication: A population-based study. Int. Health 2019, ihz089. [Google Scholar] [CrossRef] [PubMed]
- Lara, M.; Amigo, H. Association between education and blood lipid levels as income increases over a decade: A cohort study. BMC Public Health 2018, 18, 286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pampel, F.C.; Krueger, P.M.; Denney, J.T. Socioeconomic disparities in health behaviors. Annu. Rev. Sociol. 2010, 36, 349–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Level of Education | Total Cohort | Men | Women | p |
---|---|---|---|---|
Total cholesterol (M ± SD), mmol/L | ||||
Primary | 5.39 ± 1.21 n = 919 | 5.22 ± 1.16 n = 390 | 5.52 ± 1.22 c n = 529 | 0.000 |
Secondary | 5.48 ± 1.20 c n = 11078 | 5.32 ± 1.17 n = 4033 | 5.57 ± 1.21 c n = 7045 | 0.000 |
Higher | 5.34 ± 1.15 b n = 9168 | 5.29 ± 1.15 n = 3515 | 5.37 ± 1.15 a,b n = 5653 | 0.002 |
LDL-cholesterol (M ± SD), mmol/L | ||||
Primary | 3.45 ± 1.04 c n = 919 | 3.35 ± 1.01 n = 390 | 3.52 ± 1.05 c n = 529 | 0.004 |
Secondary | 3.45 ± 1.04 c n = 11079 | 3.37 ± 1.01 n = 4034 | 3.49 ± 1.05 c n = 7045 | 0.000 |
Higher | 3.33 ± 1.00 a,b n = 9168 | 3.36 ± 0.97 n = 3515 | 3.31 ± 1.02 a,b n = 5653 | 0.004 |
Triglycerides (Me [Q1; Q3]), mmol/L | ||||
Primary | 1.26 [0.89; 1.82] c n = 919 | 1.21 [0.86; 1.82] n = 390 | 1.30 [0.93; 1.80] c n = 529 | 0.111 |
Secondary | 1.26 [0.89; 1.82] c n = 11078 | 1.29 [0.90; 1.91] n = 4034 | 1.24 [0.89; 1.77] c n = 7044 | 0.000 |
Higher | 1.12 [0.79; 1.64] a,b n = 9168 | 1.23 [0.88; 1.85] n = 3515 | 1.04 [0.75; 1.52] a,b n = 5653 | 0.000 |
HDL-cholesterol (M ± SD), mmol/L | ||||
Primary | 1.37 ± 0.35 c n = 919 | 1.30 ± 0.34 b n = 390 | 1.43 ± 0.34 c n = 529 | 0.000 |
Secondary | 1.40 ± 0.35 c n = 11079 | 1.30 ± 0.33 n = 4034 | 1.45 ± 0.35 c n = 7045 | 0.000 |
Higher | 1.42 ± 0.35 a,b n = 9168 | 1.29 ± 0.33 n = 3515 | 1.50 ± 0.35 a,b n = 5653 | 0.000 |
Lp(a) (Me [Q1; Q3]), mg/dL | ||||
Primary | 13.00 [5.50; 28.25] c n = 555 | 11.60 [4.27; 26.52] n = 224 | 13.70 [6.70; 29.05] c n = 331 | 0.011 |
Secondary | 11.30 [5.00; 27.28] c n = 5338 | 9.70 [4.20; 23.40] n = 1771 | 12.40 [5.40; 29.00] c n = 3567 | 0.000 |
Higher | 10.60 [4.50; 25.40] a,b n = 4537 | 9.80 [4.20; 22.10] n = 1768 | 10.90 [4.70; 27.20] a,b n = 2769 | 0.002 |
apo AI (M ± SD), g/L | ||||
Primary | 1.55 ± 0.38 b n = 587 | 1.47 ± 0.35 b n = 239 | 1.60 ± 0.39 n = 348 | 0.000 |
Secondary | 1.60 ± 0.42 a n = 5846 | 1.55 ± 0.49 a,c n = 1937 | 1.62 ± 0.38 c n = 3909 | 0.000 |
Higher | 1.59 ± 0.39 n = 5374 | 1.49 ± 0.37 b n = 2081 | 1.65 ± 0.39 b n = 3293 | 0.000 |
apo B (M ± SD), g/L | ||||
Primary | 0.95 ± 0.27 c n = 588 | 0.93 ± 0.25 n = 239 | 0.96 ± 0.27 c n = 349 | 0.18 |
Secondary | 0.94 ± 0.26 c n = 5870 | 0.92 ± 0.26 c n = 1948 | 0.95 ± 0.27 c n = 3922 | 0.001 |
Higher | 0.89 ± 0.25 a,b n = 5393 | 0.90 ± 0.24 b n = 2088 | 0.89 ± 0.26 a,b n = 3305 | 0.002 |
apo B/apo AI (Me [Q1; Q3]) | ||||
Primary | 0.62 [0.47; 0.78] b,c n = 587 | 0.63 [0.50; 0.80] n = 239 | 0.62 [0.46; 0.77] c n = 348 | 0.161 |
Secondary | 0.59 [0.45; 0.76] a,c n = 5846 | 0.59 [0.45; 0.78] n = 1937 | 0.58 [0.45; 0.75] c n = 3909 | 0.023 |
Higher | 0.56 [0.43; 0.73] a,b n = 5373 | 0.61 [0.46; 0.78] n = 2080 | 0.53 [0.40; 0.69] a,b n = 3293 | 0.000 |
Place of Residence | Total Cohort | Men | Women | p |
---|---|---|---|---|
Total cholesterol (M ± SD), mmol/L | ||||
Urban | 5.40 ± 1.18 b n = 17133 | 5.30 ± 1.15 n = 6479 | 5.45 ± 1.19 b n = 10,654 | 0.000 |
Rural | 5.50 ± 1.20 a n = 4032 | 5.31 ± 1.19 n = 1459 | 5.61 ± 1.19 a n = 2573 | 0.000 |
LDL-cholesterol (M ± SD), mmol/L | ||||
Urban | 3.38 ± 1.02 b n = 17133 | 3.37 ± 0.99 b n = 6479 | 3.39 ± 1.04 b n = 10,654 | 0.815 |
Rural | 3.45 ± 1.03 a n = 4032 | 3.31 ± 1.02 a n = 1459 | 3.53 ± 1.03 a n = 2573 | 0.000 |
Triglycerides (Me [Q1; Q3]), mmol/L | ||||
Urban | 1.19 [0.84; 1.73] b n = 17,132 | 1.26 [0.89; 1.87] n = 6479 | 1.14 [0.81; 1.65] b n = 10,653 | 0.000 |
Rural | 1.23 [0.88; 1.78] a n = 4032 | 1.26 [0.89; 1.93] n = 1459 | 1.21 [0.87; 1.72] a n = 2573 | 0.003 |
HDL-cholesterol (M ± SD), mmol/L | ||||
Urban | 1.40 ± 0.35 b n = 17,133 | 1.29 ± 0.33 b n = 6479 | 1.47 ± 0.35 b n = 10,654 | 0.000 |
Rural | 1.43 ± 0.34 a n = 4032 | 1.32 ± 0.32 a n = 1459 | 1.49 ± 0.34 a n = 2573 | 0.000 |
Lp(a) (Me [Q1; Q3]), mg/dL | ||||
Urban | 10.70 [4.70; 26.70] b n = 7914 | 9.70 [4.10; 22.80] n = 2997 | 11.30 [5.00; 28.30] b n = 4917 | 0.000 |
Rural | 12.50 [5.10; 26.83] a n = 2516 | 10.40 [4.40; 23.95] n = 766 | 13.30 [5.40; 27.60] a n = 1750 | 0.000 |
apo AI (M ± SD), g/L | ||||
Urban | 1.57 ± 0.40 b n = 9290 | 1.50 ± 0.43 b n = 3490 | 1.61 ± 0.37 b n = 5800 | 0.000 |
Rural | 1.67 ± 0.41 a n = 2516 | 1.59 ± 0.37 a n = 766 | 1.70 ± 0.42 a n = 1750 | 0.000 |
apo B (M ± SD), g/L | ||||
Urban | 0.92 ± 0.27 b n = 9334 | 0.91 ± 0.26 n = 3508 | 0.93 ± 0.27 b n = 5826 | 0.081 |
Rural | 0.90 ± 0.23 a n = 2516 | 0.90 ± 0.23 n = 766 | 0.89 ± 0.23 a n = 1750 | 0.323 |
apo B/apo AI (Me [Q1; Q3]) | ||||
Urban | 0.59 [0.45; 0.76] b n = 9289 | 0.62 [0.47; 0.8] b n = 3489 | 0.58 [0.44; 0.74] b n = 5800 | 0.000 |
Rural | 0.53 [0.41; 0.68] a n = 2516 | 0.55 [0.44; 0.73] a n = 766 | 0.52 [0.41; 0.67] a n = 1750 | 0.000 |
Income Level | Total Cohort | Men | Women | p |
---|---|---|---|---|
Total cholesterol (M ± SD), mmol/L | ||||
Low | 5.51 ± 1.21 b,c n = 3539 | 5.28 ± 1.18 n = 941 | 5.60 ± 1.21 b,c n = 2598 | 0.000 |
Middle | 5.42 ± 1.18 a,c n = 13,547 | 5.29 ± 1.15 n = 4938 | 5.49 ± 1.19 a,c n = 8609 | 0.000 |
High | 5.32 ± 1.14 a,b n = 3784 | 5.33 ± 1.15 n = 1907 | 5.31 ± 1.13 a,b n = 1877 | 0.585 |
LDL-cholesterol (M ± SD), mmol/L | ||||
Low | 3.46 ± 1.04 b,c n = 3539 | 3.31 ± 1.01 n = 941 | 3.52 ± 1.04 b,c n = 2598 | 0.000 |
Middle | 3.40 ± 1.02 a,c n = 13548 | 3.35 ± 0.98 n = 4939 | 3.42 ± 1.04 a,c n = 8609 | 0.004 |
High | 3.33 ± 1.01 a,b n = 3784 | 3.40 ± 1.00 n = 1907 | 3.26 ± 1.01 a,b n = 1877 | 0.000 |
Triglycerides (Me [Q1; Q3]), mmol/L | ||||
Low | 1.28 [0.91; 1.84] b,c n = 3539 | 1.27 [0.92; 1.9] b,c n = 941 | 1.28 [0.91; 1.81] b,c n = 2598 | 0.631 |
Middle | 1.20 [0.85; 1.75] a,c n = 13,548 | 1.26 [0.89; 1.89] n = 4939 | 1.16 [0.83; 1.68] a,c n = 8609 | 0.000 |
High | 1.12 [0.78; 1.63] a,b n = 3783 | 1.26 [0.87; 1.87] n = 1907 | 0.99 [0.73; 1.43] a,b n = 1876 | 0.000 |
HDL-cholesterol (M ± SD), mmol/L | ||||
Low | 1.39 ± 0.34 b,c n = 3539 | 1.29 ± 0.34 b,c n = 941 | 1.42 ± 0.34 b,c n = 2598 | 0.000 |
Middle | 1.41 ± 0.35 a n = 13,548 | 1.30 ± 0.33 a,c n = 4939 | 1.47 ± 0.35 a,c n = 8609 | 0.000 |
High | 1.41 ± 0.35 a n = 3784 | 1.29 ± 0.32 a,b n = 1907 | 1.53 ± 0.34 a,b n = 1877 | 0.000 |
Lp(a) (Me [Q1; Q3]), mg/dL | ||||
Low | 12.00 [5.30; 29.75] b,c n = 1794 | 12.40 [5.30; 32.65] b,c n = 439 | 11.90 [5.30; 28.40] c n = 1355 | 0.899 |
Middle | 11.30 [4.90; 27] a,c n = 6475 | 9.60 [4.10; 22.40] a n = 2185 | 12.20 [5.30; 28.40] c n = 4290 | 0.000 |
High | 9.50 [4.30; 22.02] a,b n = 1952 | 9.50 [4.12; 20.35] a n = 1030 | 9.60 [4.50; 25.00] a,b n = 922 | 0.113 |
apo AI (M ± SD), g/L | ||||
Low | 1.51 ± 0.37 b,c n = 1952 | 1.45 ± 0.39 b,c n = 469 | 1.54 ± 0.36 b,c n = 1483 | 0.000 |
Middle | 1.60 ± 0.39 a n = 7244 | 1.53 ± 0.39 a n = 2431 | 1.64 ± 0.38 a,c n = 4813 | 0.000 |
High | 1.59 ± 0.40 a n = 2372 | 1.50 ± 0.36 a n = 1230 | 1.70 ± 0.41 a,b n = 1142 | 0.000 |
apo B (M ± SD), g/L | ||||
Low | 0.93 ± 0.25 b,c n = 1962 | 0.92 ± 0.25 n = 475 | 0.94 ± 0.25 c n = 1487 | 0.268 |
Middle | 0.92 ± 0.26 a,c n = 7272 | 0.91 ± 0.25 n = 2440 | 0.93 ± 0.27 c n = 4832 | 0.012 |
High | 0.89 ± 0.25 a,b n = 2378 | 0.91 ± 0.25 n = 1233 | 0.86 ± 0.24 a,b n = 1145 | 0.000 |
apo B/apo AI (Me [Q1;Q3]) | ||||
Low | 0.63 [0.49; 0.79] b,c n = 1952 | 0.65 [0.50; 0.82] b,c n = 469 | 0.62 [0.48; 0.78] b,c n = 1483 | 0.010 |
Middle | 0.57 [0.44; 0.74] a,c n = 7243 | 0.60 [0.45; 0.78] a n = 2430 | 0.56 [0.43; 0.73] a,c n = 4813 | 0.000 |
High | 0.55 [0.42; 0.73] a,b n = 2372 | 0.61 [0.47; 0.79] a n = 1230 | 0.50 [0.39; 0.65] a,b n = 1142 | 0.000 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Metelskaya, V.A.; Shalnova, S.A.; Yarovaya, E.B.; Kutsenko, V.A.; Boytsov, S.A.; Shlyakhto, E.V.; Drapkina, O.M. Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study. Int. J. Environ. Res. Public Health 2022, 19, 931. https://doi.org/10.3390/ijerph19020931
Metelskaya VA, Shalnova SA, Yarovaya EB, Kutsenko VA, Boytsov SA, Shlyakhto EV, Drapkina OM. Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study. International Journal of Environmental Research and Public Health. 2022; 19(2):931. https://doi.org/10.3390/ijerph19020931
Chicago/Turabian StyleMetelskaya, Victoria A., Svetlana A. Shalnova, Elena B. Yarovaya, Vladimir A. Kutsenko, Sergey A. Boytsov, Eugeny V. Shlyakhto, and Oxana M. Drapkina. 2022. "Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study" International Journal of Environmental Research and Public Health 19, no. 2: 931. https://doi.org/10.3390/ijerph19020931